S. Tanasanvimon

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

P. Philip, A. Zhu, M. Borad, 2021, The lancet. Gastroenterology & hepatology.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer

E. Oki, C. Ishioka, R. Chacko, 2023, ESMO open.